Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2
diabetes mellitus, show promise in promoting weight loss and improving heart health in …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Objective To determine effects of glucagon-like peptide-1 (GLP-1) receptor agonists on≥
5% or≥ 10% weight loss in overweight or obese patients with or without type 2 diabetes …

Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) reduce elevated blood glucose
levels and induce weight loss. Multiple GLP‐1 RAs and one combined GLP‐1/glucose …

Glucagon‐Like Peptide‐1 receptor agonists (GLP‐1RAs), approved as glucose‐lowering
drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An …

To evaluate the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on
weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta …

Abstract Purpose of Review The burden of obesity worldwide is high and projected to rise.
Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk …

Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can
improve many obesity-related complications. Despite the benefits of weight reduction, there …